HR Execs on the Move

NGM Biopharmaceuticals

www.ngmbio.com

 
NGM Bio is a research-driven, clinical-stage biopharmaceutical company with a passion to improve the lives of those struggling with serious diseases. Our expertise in drug discovery and translational development, coupled with the significant resources from our partnership with Merck, is driving development of transformational medicines that dramatically improve human health. Our initial R&D focus has been to develop a portfolio of high-impact therapeutics for the underserved patient populations who suffer from cardio-metabolic and liver diseases. We believe that our research expertise – comprehensive and grounded in fundamental, interrelated mechanisms of human biology – is capable of driving the development of ...
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.ngmbio.com
  • 333 Oyster Point Boulevard
    South San Francisco, CA USA 94080
  • Phone: 650.243.5555

Executives

Name Title Contact Details
Sujin Key
 Director, Clinical Supply Chain and CMC Ops Profile
Courtney Grafe
 Director Talent Acquisition Profile
Jessica Ferreyra
 Chief Of Staff Profile
Brian Muma
 Vice President, Human Resources Profile

Similar Companies

Lower Valley Ambulance

Lower Valley Ambulance is a Cheswick, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Clinical Research Consultants

Clinical Research Consultants is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tactical Therapeutics

Tactical Therapeutics is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Contextual Genomics

Transforming cancer care with data driven medicine

Plexium

Plexium is the premier, next-generation Targeted Protein Degradation (TPD) company seeking to discover a wide range of monovalent target protein degraders that address the limitations of heterobifunctional degraders and cereblon IMiDs. The company is powered by its proprietary drug discovery platform designed to identify novel small molecules that induce selective degradation of drug target proteins through E3 ligase mediated proteasomal degradation. From molecular glues to monovalent degraders, Plexium is advancing a pipeline of novel targeted protein degraders for the treatment of cancer, neurodegeneration, and other diseases. Due to its expertise in TPD, Plexium has entered into strategic collaborations with Amgen and AbbVie to discover and develop a wide range of new therapies from cancer to neurological diseases. Supported by high quality investors, Plexium is well positioned to transform medicine.